Taryn Rogalski-Salter

As head of global regulatory strategy and operations at the Bill & Melinda Gates Medical Research Institute, Taryn Rogalski-Salter, Ph.D., and her team develops and implements innovative global regulatory strategies that support accelerated product development, playing a critical role in helping to advance drug and vaccine candidates toward licensure globally.

Throughout her 25-year career in manufacturing, analytical development, global regulatory policy, and regulatory affairs, Taryn has been directly involved in the global licensure of nearly a dozen new vaccines. Prior to joining the Institute, Taryn was vice president and head of global regulatory affairs at Takeda Vaccines, where she was responsible for all regulatory aspects including norovirus, dengue, sIPV, and Zika vaccine candidates. From 2008 to 2012, Taryn served as vice president and global head of vaccine regulatory affairs at Novartis Vaccines & Diagnostics, achieving global licensure of vaccines for influenza and meningitis. As vice president of global regulatory Chemistry, Manufacturing, and Controls (CMC) at Novartis Pharmaceuticals Corporation from 2007 to 2008, she was responsible for all CMC aspects concerning developmental and marketed products. Prior to her work at Novartis, she held various leadership roles in regulatory affairs and global regulatory policy at Merck and GlaxoSmithKline from 1994 to 2007.

Taryn has extensive experience in global regulatory policy and has occupied elected and volunteer positions in pharmaceutical trade organizations including PhRMA, BIO, and IFPMA. Taryn received her Ph.D. from Dartmouth College and conducted her thesis research on applied genetic and metabolic engineering at Dartmouth's Thayer School.